Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 11/20 | 0.57 |
| ▸ | KAT7 | O95251 | 10/20 | 0.57 |
| ▸ | KAT6B | Q8WYB5 | 7/20 | 0.57 |
| ▸ | KAT5 | Q92993 | 4/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652563 | 1.00 | KAT6A (0.57) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL29652583 | 0.93 | KAT6A (0.59) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL21609074 | 0.93 | KAT6A (0.59) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL21609006 | 0.92 | KAT6A (0.57) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL29652576 | 0.92 | KAT6A (0.57) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL21609167 | 0.91 | KAT6A (0.63) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL21596823 | 0.87 | KAT6A (0.59) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL21609159 | 0.86 | KAT6A (0.59) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL21596889 | 0.86 | KAT6A (0.59) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL31605586 | 0.86 | KAT6A (0.69) | KAT6AKAT7KAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | KAT6A 877/4885KAT7 490/4885KAT6B 1005/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | KAT6A 878/4885KAT7 490/4885KAT6B 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.